Cambridge Healthtech Institute’s Fifteenth Annual Biomarker World Congress is the longest-running event dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines. With the promising developments in immuno-oncology over the past five years, much of the biomarker R&D has shifted to discovery and development of predictive biomarkers for immunotherapy patient stratification, using biomarker or mechanism data to choose rational combination immunotherapy, and applying immune profiling to predict response to immunotherapy. Latest advances in clinical and translational biomarkers will also be covered, including patient selection and predicting response to therapy, liquid biopsy and cell free DNA, companion diagnostics and personalized medicine, biomarker assay development and validation, and biomarker-based clinical trials. Finally, the new frontier of digital health and its impact on drug and diagnostic development will be explored in a comprehensive program covering emerging digital biomarkers and their utility in clinical trials, advances in biosensors and wearables as clinical endpoints, integration of mobile health into drug development, and the latest applications of Internet of Things (IoT) and smartphones in point-of-care testing and remote patient monitoring. Please join us for comprehensive scientific coverage and unparalleled networking opportunities at the Fifteenth Annual Biomarker World Congress 2019! The Congress is part of Cambridge Healthtech Institute’s World Pharma Week: the premier meeting place for pharmaceutical decision makers!
» Internet of Diagnostic Things
» Immuno-Oncology Biomarkers 1: Predictive Biomarkers and Companion Diagnostics (Shared Conference with IO Pharma Congress)
» Clinical and Translational Biomarkers